An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2027

Conditions

Immune Thrombocytopenia (ITP)Treatment

Interventions

DRUG

CM336 Injection

subcutaneous CM336 administration step-up dosing Dose and frequency of CM336 according to the protocol

Trial Locations (1)

RECRUITING

Chinese Academy of Medical Science and Blood Disease Hospital, Tianjin

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER